CsA exposure is associated with acute GVHD and relapse in children after SCT

Bone Marrow Transplantation

Volumn 45, Issue 6, 2010, Pages 1056-1061

  Willemze, A J ^a   Press, R R ^a   Lankester, A C ^a   Egeler, R M ^a   Den Hartigh, J ^a   Vossen, J M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

children; CsA; outcome; pharmacokinetics; SCT

Indexed keywords

CYCLOSPORIN A; METHOTREXATE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG MONITORING; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT OUTCOME; ACUTE DISEASE; CHEMICALLY INDUCED; FEMALE; HEMATOLOGIC NEOPLASMS; INFANT; MALE; PRESCHOOL CHILD; RECURRENT DISEASE; SURVIVAL RATE;

ACUTE DISEASE; ADOLESCENT; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; DRUG MONITORING; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77954865872     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.299     Document Type: Article

References (27)

1. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729-735. (Pubitemid 16124386)
2. Ruutu T, Niederwieser D, Gratwohl A, Apperley JF. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT. Bone Marrow Transplant 1997; 19: 759-764.
3. Cooney GF, Habucky K, Hoppu K. Cyclosporin pharmacokinetics in paediatric transplant recipients. Clin Pharmacokinet 1997; 32: 481-495.
4. Schrauder A, Saleh S, Sykora KW, Hoy H, Welte K, Boos J et al. Pharmacokinetic monitoring of intravenous cyclosporine A in pediatric stem-cell transplant recipients. The trough level is not enough. Pediatr Transplant 2009; 13: 444-450.
5. Knight SR, Morris PJ. The clinical benefits of cyclosporine C2-level monitoring: a systematic review. Transplantation 2007; 83: 1525-1535.
6. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993; 54: 205-218.
7. del Mar Fernandez De Gatta M, Santos-Buelga D, Dominguez-Gil A, Garcia MJ. Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations. Clin Pharmacokinet 2002; 41: 115-135.
8. Vossen JM, Heidt PJ, van den BH, Gerritsen EJ, Hermans J, Dooren LJ. Prevention of infection and graft-versus-host disease by suppression of intestinal microflora in children treated with allogeneic bone marrow transplantation. Eur J Clin Microbiol Infect Dis 1990; 9: 14-23.
9. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
10. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
11. Willemze AJ, Cremers SC, Schoemaker RC, Lankester AC, den Hartigh J, Burggraaf J et al. Ciclosporin kinetics in children after stem cell transplantation. Br J Clin Pharmacol 2008; 66: 539-545.
12. Beal SL, Sheiner LB, Boeckmann AJ (eds). NONMEM Users Guides (1989-2006). Icon Development Solutions, Ellicott City, MD, USA, 2007.
13. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008; 48: 303-332.
14. Ghalie R, Fitzsimmons WE, Weinstein A, Manson S, Kaizer H. Cyclosporine monitoring improves graft-versus-host disease prophylaxis after bone marrow transplantation. Ann Pharmacother 1994; 28: 379-383.
15. Martin P, Bleyzac N, Souillet G, Galambrun C, Bertrand Y, Maire PH et al. Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors. Bone Marrow Transplant 2003; 32: 881-887. (Pubitemid 37369265)
16. Przepiorka D, Shapiro S, Schwinghammer TL, Bloom EJ, Rosenfeld CS, Shadduck RK et al. Cyclosporine and methylprednisolone after allogeneic marrow transplantation: association between low cyclosporine concentration and risk of acute graftversus-host disease. Bone Marrow Transplant 1991; 7: 461-465.
17. Punnett A, Sung L, Price V, Das P, Diezi M, Doyle J et al. Achievement of target cyclosporine concentrations as a predictor of severe acute graft versus host disease in children undergoing hematopoietic stem cell transplantation and receiving cyclosporine and methotrexate prophylaxis. Ther Drug Monit 2007; 29: 750-757.
18. Yee GC, Self SG, McGuire TR, Carlin J, Sanders JE, Deeg HJ. Serum cyclosporine concentration and risk of acute graftversus-host disease after allogeneic marrow transplantation. N Engl J Med 1988; 319: 65-70.
19. Cole E, Keown P, Landsberg D, Halloran P, Shoker A, Rush D et al. Safety and tolerability of cyclosporine and cyclosporine microemulsion during 18 months of follow-up in stable renal transplant recipients: a report of the Canadian Neoral Renal Study Group. Transplantation 1998; 65: 505-510. (Pubitemid 28136492)
20. International Neoral Renal Transplantation Study Group. Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant 2002; 2: 148-156.
21. Barkholt L, Remberger M, Bodegard H, Ringden O, Bottiger Y. Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 40: 683-689.
22. Locatelli F, Zecca M, Rondelli R, Bonetti F, Dini G, Prete A et al. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. Blood 2000; 95: 1572-1579. (Pubitemid 30120815)
23. Porter DL, Collins RH, Hardy C, Kernan NA, Drobyski WR, Giralt S et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 2000; 95: 1214-1221.
24. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
25. Cardoso AA, Schultze JL, Boussiotis VA, Freeman GJ, Seamon MJ, Laszlo S et al. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood 1996; 88: 41-48.
26. Pons G, Treluyer JM, Dimet J, Merle Y. Potential benefit of Bayesian forecasting for therapeutic drug monitoring in neonates. Ther Drug Monit 2002; 24: 9-14.
27. Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: general principles. Eur J Pediatr 2006; 165: 741-746. (Pubitemid 44440510)